Lisata Therapeutics Reports Q1 2026 Financial Results with $4.5M Net Loss

Lisata Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $4.5 million, a slight improvement from the $4.7 million loss recorded in the same period of 2025. The company's total operating expenses decreased to $4.9 million, down from $5.8 million year-over-year, primarily due to a significant reduction in research and development costs, which fell by 53.7% to approximately $1.2 million. This decline was attributed to the completion of the Phase 2a Bolster trial and a reduction in clinical department expenses following staff reductions in the previous year. General and administrative expenses, however, increased by 15.2% to $3.7 million, driven by higher legal and consulting fees related to the proposed acquisition by Kuva Labs Inc.

As of March 31, 2026, Lisata held cash and cash equivalents of approximately $13.1 million, a decrease from $15.9 million at the end of 2025. The company’s total assets also declined to $14.1 million from $17.7 million, while total liabilities increased slightly to $3.4 million. The company’s stockholders' equity decreased to $10.9 million from $14.9 million, reflecting the ongoing operational losses. The weighted average shares outstanding increased to 9.1 million from 8.6 million, resulting in a basic and diluted loss per share of $0.50, compared to $0.55 in the prior year.

Strategically, Lisata is navigating a proposed acquisition by Kuva Labs, which was formalized through a merger agreement on March 6, 2026. Under the terms, Kuva intends to purchase all outstanding shares of Lisata for $5.00 per share, plus a contingent value right (CVR) that could yield an additional $1.00 per share if certain regulatory milestones are met. The timeline for the tender offer has been extended multiple times, with the latest deadline set for May 29, 2026. The completion of this transaction would result in Lisata becoming a privately held entity, with its shares delisted from Nasdaq.

Operationally, Lisata has been focusing on its investigational product, certepetide, which is designed to enhance the delivery of anti-cancer therapies to solid tumors. The company has been involved in several clinical trials, including ongoing studies in various solid tumor types. However, the company has not generated any revenue during the reported quarter, continuing a trend from the previous year. The lack of revenue underscores the company's reliance on external funding and strategic partnerships to support its research and development efforts.

Looking ahead, Lisata's management has expressed substantial doubt regarding the company's ability to continue as a going concern for the next twelve months, primarily due to its history of operating losses and the need for additional capital. The company is exploring various funding avenues, including potential equity or debt offerings, to meet its operational needs. The outcome of the proposed acquisition by Kuva Labs will also significantly impact Lisata's future financial stability and operational direction.